BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21277646)

  • 1. Telomerase activity in pleural malignant mesotheliomas.
    Au AY; Hackl T; Yeager TR; Cohen SB; Pass HI; Harris CC; Reddel RR
    Lung Cancer; 2011 Sep; 73(3):283-8. PubMed ID: 21277646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomerase activity in human pleural mesothelioma.
    Dhaene K; Hübner R; Kumar-Singh S; Weyn B; Van Marck E
    Thorax; 1998 Nov; 53(11):915-8. PubMed ID: 10193387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.
    Tallet A; Nault JC; Renier A; Hysi I; Galateau-Sallé F; Cazes A; Copin MC; Hofman P; Andujar P; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Oncogene; 2014 Jul; 33(28):3748-52. PubMed ID: 23975423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SV40 infection induces telomerase activity in human mesothelial cells.
    Foddis R; De Rienzo A; Broccoli D; Bocchetta M; Stekala E; Rizzo P; Tosolini A; Grobelny JV; Jhanwar SC; Pass HI; Testa JR; Carbone M
    Oncogene; 2002 Feb; 21(9):1434-42. PubMed ID: 11857086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomere maintenance mechanisms in cancer: telomerase, ALT or lack thereof.
    Claude E; Decottignies A
    Curr Opin Genet Dev; 2020 Feb; 60():1-8. PubMed ID: 32114293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of alternative lengthening of telomeres mechanisms in carcinogenesis and prospects for using an anti-telomerase drugs in malignant tumors treatment].
    Grach AA
    Tsitologiia; 2011; 53(10):759-71. PubMed ID: 22232932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay.
    Hansson M; Zendehrokh N; Ohyashiki J; Ohyashiki K; Westman UB; Roos G; Dejmek A
    Arch Pathol Lab Med; 2008 Dec; 132(12):1896-902. PubMed ID: 19061286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human sarcomas are mosaic for telomerase-dependent and telomerase-independent telomere maintenance mechanisms: implications for telomere-based therapies.
    Gocha AR; Nuovo G; Iwenofu OH; Groden J
    Am J Pathol; 2013 Jan; 182(1):41-8. PubMed ID: 23260199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative lengthening of telomeres is induced by telomerase inhibitors in Barrett's esophageal cells.
    Qin X; Qi B; Zhao B
    Oncol Rep; 2013 Apr; 29(4):1399-404. PubMed ID: 23338150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup.
    Pirker C; Bilecz A; Grusch M; Mohr T; Heidenreich B; Laszlo V; Stockhammer P; Lötsch-Gojo D; Gojo J; Gabler L; Spiegl-Kreinecker S; Dome B; Steindl A; Klikovits T; Hoda MA; Jakopovic M; Samarzija M; Mohorcic K; Kern I; Kiesel B; Brcic L; Oberndorfer F; Müllauer L; Klepetko W; Schmidt WM; Kumar R; Hegedus B; Berger W
    Clin Cancer Res; 2020 Jul; 26(14):3819-3830. PubMed ID: 32317288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma.
    Villa R; Daidone MG; Motta R; Venturini L; De Marco C; Vannelli A; Kusamura S; Baratti D; Deraco M; Costa A; Reddel RR; Zaffaroni N
    Clin Cancer Res; 2008 Jul; 14(13):4134-40. PubMed ID: 18593991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomere maintenance in Wilms tumors: first evidence for the presence of alternative lengthening of telomeres mechanism.
    Venturini L; Daidone MG; Motta R; Collini P; Spreafico F; Terenziani M; Piva L; Radice P; Perotti D; Zaffaroni N
    Genes Chromosomes Cancer; 2011 Oct; 50(10):823-9. PubMed ID: 21769957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression profile of telomerase subunits in human pleural mesothelioma.
    Dhaene K; Wauters J; Weyn B; Timmermans JP; van Marck E
    J Pathol; 2000 Jan; 190(1):80-5. PubMed ID: 10640996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbonic anhydrase IX in malignant pleural mesotheliomas: a potential target for anti-cancer therapy.
    Kivelä AJ; Knuuttila A; Räsänen J; Sihvo E; Salmenkivi K; Saarnio J; Pastorekova S; Pastorek J; Waheed A; Sly WS; Salo JA; Parkkila S
    Bioorg Med Chem; 2013 Mar; 21(6):1483-8. PubMed ID: 23036334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).
    De Vitis M; Berardinelli F; Sgura A
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The telomere maintenance mechanism spectrum and its dynamics in gliomas.
    Kim S; Chowdhury T; Yu HJ; Kahng JY; Lee CE; Choi SA; Kim KM; Kang H; Lee JH; Lee ST; Won JK; Kim KH; Kim MS; Lee JY; Kim JW; Kim YH; Kim TM; Choi SH; Phi JH; Shin YK; Ku JL; Lee S; Yun H; Lee H; Kim D; Kim K; Hur JK; Park SH; Kim SK; Park CK
    Genome Med; 2022 Aug; 14(1):88. PubMed ID: 35953846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALT: A Multi-Faceted Phenomenon.
    Sommer A; Royle NJ
    Genes (Basel); 2020 Jan; 11(2):. PubMed ID: 32012790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immortal ALT+ human cells do not require telomerase reverse transcriptase for malignant transformation.
    Sun B; Chen M; Hawks CL; Hornsby PJ
    Cancer Res; 2005 Aug; 65(15):6512-5. PubMed ID: 16061628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
    Akter J; Kamijo T
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Simian Virus 40 (SV40) Have a Role in UK Malignant Pleural Mesothelioma? No Role is Identified in a Sensitive RNA In Situ Hybridization Study on Potentially Affected Birth Cohorts.
    Alchami FS; Attanoos RL; Gibbs A; Morgan F; Jasani B
    Appl Immunohistochem Mol Morphol; 2020 Jul; 28(6):444-447. PubMed ID: 31205069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.